ELVN vs TNGX
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
ELVN · Enliven Therapeutics$46.53 ▲ 0.26%
TNGX · Tango Therapeutics$21.73 ▼ 4.32%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- ELVN +113.7%
- TNGX +110.4%
Head to head
| Metric | ELVN | TNGX |
|---|---|---|
| Price | $46.53 | $21.73 |
| Change today | ▲ 0.26% | ▼ 4.32% |
| Market cap | $3.42B | $3.68B |
| Return, 3 months | -23.9% | -11.3% |
| Return, year to date | +202.1% | +145.3% |
| Return, 1 year | +113.9% | +116.7% |
| P/E (TTM) | – | – |
| P/B | 3.9 | 3.8 |
| P/E percentile vs own 5y | 19th | 14th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | – | -100.0% |
| Net profit growth (YoY) | -37.5% | -530.6% |
| Gross margin | – | – |
| Operating margin | – | – |
| Net margin | – | – |
| Return on equity | -16.8% | -36.5% |
| Analyst target vs. price | +60.9% | +124.0% |
| Analyst buy share | 100% | 100% |
| RSI (14) | 50 | 44 |
| 30-day volatility | 56.9% | 95.4% |
| Max drawdown, 1 year | -39.0% | -36.6% |
| Trend read | Leaning bullish | Strong downtrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- TNGX is the largest of the group by market value.
- TNGX has returned the most over the past year.
- ELVN has been the calmest stock over the last 30 days.